AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28778920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly impaired physical and mental health (22% of patients)
Number of subjects: 645
Study 28778920 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately impaired physical and mental health (39%)
Number of subjects: 645
Study 28778920 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely impaired physical health with moderately impaired mental health (15%)
Number of subjects: 645
Study 28778920 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely impaired physical and mental health (24%)
Number of subjects: 645
Study 28778920 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification rule adequacy
Number of subjects: 645
Study 28778920 — intervention group
Group type: EXPERIMENTAL
Intervention: Female Latino smokers
Number of subjects: 645
Study 28778920 — intervention group
Group type: EXPERIMENTAL
Intervention: Male non-Latino non-smokers
Number of subjects: 645
Study 25171881 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic sphincter augmentation (MSAD)
Number of subjects: 249
Study 25171881 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic fundoplication (LF)
Number of subjects: 249
Study 23723119 — intervention group
Group type: EXPERIMENTAL
Intervention: Designing a patient education poster
Number of subjects: 329
Study 23723119 — intervention group
Group type: COMPARATOR
Intervention: Case‐oriented education (control group)
Number of subjects: 329
Study 21192940 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone (150 mg BID) during the follicular phase
Number of subjects: 10
Study 21192940 — intervention group
Group type: COMPARATOR
Intervention: Normal follicular phase
Number of subjects: 10
Study 21192940 — intervention group
Group type: COMPARATOR
Intervention: Normal luteal phase
Number of subjects: 10
Study 18492838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of phytosterols and (n‐3) LCPUFA
Number of subjects: 60
Study 18492838 — intervention group
Group type: COMPARATOR
Intervention: (n‐3) LCPUFA alone
Number of subjects: 60
Study 16538000 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (GP group)
Number of subjects: 34
Study 16538000 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (GB group)
Number of subjects: 34
Study 16538000 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy (INS group)
Number of subjects: 34
Study 14618042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esmolol for 24 hours post-CABG followed by oral beta-blocker
Number of subjects: 50
Study 14618042 — intervention group
Group type: COMPARATOR
Intervention: Standard oral beta-blocker treatment
Number of subjects: 50
Study 11012562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily for 7 days
Number of subjects: 12
Study 11012562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9268782 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Instruction (CAI)
Number of subjects: 10
Study 9268782 — intervention group
Group type: COMPARATOR
Intervention: Interactive Lecture
Number of subjects: 10
Study 8325278 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flumazenil (30 or 100 mg)
Number of subjects: 12
Study 8325278 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (15 mg)
Number of subjects: 12
Study 8325278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3791364 — intervention group
Group type: EXPERIMENTAL
Intervention: tolciclate solution
Number of subjects: 40
Study 3791364 — intervention group
Group type: COMPARATOR
Intervention: placebo solution
Number of subjects: 40
Study 28834822 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPO
Number of subjects: 58
Study 28834822 — intervention group
Group type: COMPARATOR
Intervention: Minimal ORIF
Number of subjects: 58
Study 25946305 — intervention group
Group type: EXPERIMENTAL
Intervention: Light shoes (352 ± 18.4 g)
Number of subjects: 22
Study 25946305 — intervention group
Group type: COMPARATOR
Intervention: Heavy shoes (637 ± 17.7 g)
Number of subjects: 22
Study 23911013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5, 5, or 10 mg/day
Number of subjects: 808
Study 23911013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 23911013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 808
Study 23631622 — intervention group
Group type: EXPERIMENTAL
Intervention: Motive-Oriented Therapeutic Relationship (MOTR)
Number of subjects: 20
Study 23631622 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric-Psychodynamic Treatment
Number of subjects: 20
Study 20614193 — intervention group
Group type: EXPERIMENTAL
Intervention: Early complete lymph node dissection (early CLND)
Number of subjects: 357
Study 20614193 — intervention group
Group type: COMPARATOR
Intervention: Delayed complete lymph node dissection (delayed CLND)
Number of subjects: 357
Study 17651533 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavourless gum (Experiment 1)
Number of subjects: 0
Study 17651533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mint-flavoured strips (Experiment 2)
Number of subjects: 0
Study 17651533 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavourless gum or mint-flavoured strips
Number of subjects: 0
Study 17064498 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents (urokinase or rt-PA) for massive and sub-massive PTE
Number of subjects: 516
Study 17064498 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant agents (IV infusion of unfractioned heparin or subcutaneous low-molecular-weight heparin) for non-massive PTE
Number of subjects: 516
Study 12948097 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 0
Study 11036119 — intervention group
Group type: COMPARATOR
Intervention: Troponin T levels <0.06 microg/L
Number of subjects: 917
Study 11036119 — intervention group
Group type: COMPARATOR
Intervention: Troponin T levels 0.06 to 0.59 microg/L
Number of subjects: 917
Study 11036119 — intervention group
Group type: COMPARATOR
Intervention: Troponin T levels ≥0.60 microg/L
Number of subjects: 917
Study 11036119 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein levels <2 mg/L
Number of subjects: 917
Study 11036119 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein levels 2 to 10 mg/L
Number of subjects: 917
Study 11036119 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein levels >10 mg/L
Number of subjects: 917
Study 11036119 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen levels <3.4 g/L
Number of subjects: 917
Study 11036119 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen levels 3.4 to 3.9 g/L
Number of subjects: 917
Study 11036119 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen levels ≥4.0 g/L
Number of subjects: 917
Study 7661066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone treatment (800 mg/day for 2 weeks, then 400 mg/day thereafter)
Number of subjects: 127
Study 7661066 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiarrhythmic therapy)
Number of subjects: 127
Study 7661066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone treatment
Number of subjects: 127
Study 7661066 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 2748528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam (10 to 60 mg daily, divided doses)
Number of subjects: 21
Study 2748528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 862331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of antidiuretic hormone at a low rate for 1 hr
Number of subjects: 10
Study 862331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of antidiuretic hormone
Number of subjects: 10
Study 27353245 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release methylphenidate (Ritalin® LA at a dose of 0.6 mg/kg)
Number of subjects: 11
Study 27353245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 11
Study 27353245 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release methylphenidate
Number of subjects: 11
Study 27353245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26405006 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous (inhibitory) TBS over S1
Number of subjects: 5
Study 26405006 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous TBS over PPC
Number of subjects: 5
Study 26405006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent (excitatory) TBS over PPC
Number of subjects: 5
Study 26405006 — intervention group
Group type: COMPARATOR
Intervention: rTMS applied over M1
Number of subjects: 5
Study 24029478 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased posterior tibial slope (>6.6 degrees) in ACL rupture group
Number of subjects: 150
Study 24029478 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased slope of tibial plateau
Number of subjects: 150
Study 24029478 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased posterior slope
Number of subjects: 150
Study 24029478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACL rupture)
Number of subjects: 150
Study 21145618 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐874 (dosage not specified)
Number of subjects: 180
Study 21145618 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐874 (through the first 48 weeks)
Number of subjects: 180
Study 21145618 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐874 (during the open-label extension)
Number of subjects: 180
Study 18940114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine 1 ml/kg with tramadol 1 mg/kg body weight
Number of subjects: 60
Study 18940114 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine 1 ml/kg body weight
Number of subjects: 60
Study 16849064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bite-wafer group (BWG) - performed immediate supervised mastication of the wafers for 10 minutes and bit on the wafers to prevent pain for the next 7 days.
Number of subjects: 84
Study 16849064 — intervention group
Group type: COMPARATOR
Intervention: Reduced-mastication group (RMG) - instructed not to masticate for 3 hours after placement of the fixed appliance and to avoid masticating hard food for 7 days.
Number of subjects: 84
Study 14584858 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy using an expanded polytetrafluoroethylene (ePTFE) membrane and demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 43
Study 11103236 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin
Number of subjects: 0
Study 11103236 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 alone
Number of subjects: 0
Study 11103236 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU alone
Number of subjects: 0
Study 11103236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential methotrexate and 5‐fluorouracil
Number of subjects: 0
Study 9058218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone, 50 micrograms/kg loading dose over 20 minutes followed by 0.5 microgram/kg/min infusion
Number of subjects: 32
Study 9058218 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 32
Study 9058218 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label milrinone administered after initial failure to wean from bypass
Number of subjects: 32
Study 9058218 — intervention group
Group type: COMPARATOR
Intervention: Milrinone and placebo
Number of subjects: 32
Study 9058218 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 32
Study 8412049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg
Number of subjects: 13
Study 8412049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 6 mg
Number of subjects: 13
Study 8412049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3760657 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture medium containing no protein
Number of subjects: 100
Study 3760657 — intervention group
Group type: COMPARATOR
Intervention: Culture medium containing 10% maternal serum (Control)
Number of subjects: 100
Study 31377895 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal laser treatment (3 treatments administered 4 weeks apart)
Number of subjects: 26
Study 29546832 — intervention group
Group type: EXPERIMENTAL
Intervention: TA‐65 (16 mg daily for 12 weeks)
Number of subjects: 40
Study 29546832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27121090 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Life to the Full guided online CBT‐based life skills package with telephone or email support
Number of subjects: 0
Study 27121090 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to the Living Life to the Full guided online CBT‐based life skills package
Number of subjects: 0
Study 24782291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg/day
Number of subjects: 34
Study 24782291 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 34
Study 22431716 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod, 5%, cream 5 d/wk for 3 months
Number of subjects: 90
Study 22431716 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod, 5%, cream 5 d/wk for 3 months plus tazarotene, 0.1%, gel 2 d/wk for 3 months
Number of subjects: 90
Study 20233193 — intervention group
Group type: EXPERIMENTAL
Intervention: Document modified using systematic improvement of lexicosyntactic readability
Number of subjects: 159
Study 20233193 — intervention group
Group type: EXPERIMENTAL
Intervention: Document modified by a working group
Number of subjects: 159
Study 20233193 — intervention group
Group type: COMPARATOR
Intervention: Unchanged document (control group)
Number of subjects: 159
Study 18577931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine in combination with haloperidol
Number of subjects: 51
Study 18577931 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol only
Number of subjects: 51
Study 15854633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 mug)
Number of subjects: 160
Study 15854633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 mug)
Number of subjects: 160
Study 15854633 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral
Number of subjects: 160
Study 15854633 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal
Number of subjects: 160
Study 11793395 — intervention group
Group type: EXPERIMENTAL
Intervention: Wa x UK vaccine (P1A[8],G6); single oral dose;
Number of subjects: 0
Study 11793395 — intervention group
Group type: EXPERIMENTAL
Intervention: Wa x (DS-1 x UK) vaccine (P1A[8],G2); single oral dose;
Number of subjects: 0
Study 10890259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 600 mg QD
Number of subjects: 919
Study 10890259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg BID
Number of subjects: 919
Study 10890259 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 250 mg QID
Number of subjects: 919
Study 10890259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir (both regimens)
Number of subjects: 919
Study 10890259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 919
Study 10890259 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 919
Study 7580360 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin (2 million KIU IV at induction of anesthesia and 2 million KIU added to the extracorporeal circuit, followed by infusion of 500 thousand KIU/h during surgery)
Number of subjects: 60
Study 7580360 — intervention group
Group type: COMPARATOR
Intervention: Epsilon-aminocaproic acid (10 g IV at induction of anesthesia, followed by infusion of 2 g/h for 5 hours)
Number of subjects: 60
Study 7580360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg IV within 30 minutes after induction of anesthesia, followed by infusion of 1 mg/kg per hour for 10 hours)
Number of subjects: 60
Study 7580360 — intervention group
Group type: COMPARATOR
Intervention: Control (no antifibrinolytic therapy)
Number of subjects: 60
Study 1418152 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic catheter placement prior to selective embolization
Number of subjects: 9
Study 1418152 — intervention group
Group type: COMPARATOR
Intervention: Emergent catheter placement for selective embolization
Number of subjects: 9
Study 6370748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Ro 12‐7024 ointment
Number of subjects: 39
Study 6370748 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate ointment
Number of subjects: 39
Study 31522546 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 332
Study 31522546 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 332
Study 31522546 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS (post hoc analysis)
Number of subjects: 332
Study 31522546 — intervention group
Group type: COMPARATOR
Intervention: Sham (post hoc analysis)
Number of subjects: 332
Study 30084934 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 131
Study 30084934 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 131
Study 27213795 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliatilin (1000 mg/4ml, 12-15 doses intravenously, then 1 capsule b.i.d. for 4 months orally)
Number of subjects: 240
Study 27213795 — intervention group
Group type: COMPARATOR
Intervention: Standard neuroprotective therapy (not specified)
Number of subjects: 240
Study 24692481 — intervention group
Group type: EXPERIMENTAL
Intervention: Target systolic BP <150 mm Hg
Number of subjects: 67
Study 24692481 — intervention group
Group type: COMPARATOR
Intervention: Target systolic BP <180 mm Hg
Number of subjects: 67
Study 24692481 — intervention group
Group type: EXPERIMENTAL
Intervention: Edematous region CBF
Number of subjects: 67
Study 24692481 — intervention group
Group type: COMPARATOR
Intervention: Contralateral tissue CBF
Number of subjects: 67
Study 24692481 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP change
Number of subjects: 67
Study 24692481 — intervention group
Group type: EXPERIMENTAL
Intervention: Perihematoma relative CBF
Number of subjects: 67
Study 22745199 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT at an energy level of 0.20 mJ/mm²
Number of subjects: 46
Study 22745199 — intervention group
Group type: COMPARATOR
Intervention: ESWT at an energy level of 0.10 mJ/mm²
Number of subjects: 46
Study 22745199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 19672055 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured written and oral information about asthma and asthma medication, and asthma diary
Number of subjects: 141
Study 19672055 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 141
Study 18576945 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine (1.9, 3.8, 7.5, or 15 microg of hemagglutinin)
Number of subjects: 200
Study 18576945 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine (higher doses)
Number of subjects: 200
Study 18576945 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (7.5 microg of hemagglutinin)
Number of subjects: 200
Study 18576945 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine
Number of subjects: 200
Study 18576945 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine
Number of subjects: 200
Study 16447664 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture with lifting manipulation
Number of subjects: 180
Study 16447664 — intervention group
Group type: COMPARATOR
Intervention: Scalp acupuncture with twirling manipulation
Number of subjects: 180
Study 11989073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow up (40 patients), controlled every 2 months with physical examination and lipid profile, diet and exercise enhancement, and statin dose adjustment.
Number of subjects: 75
Study 11989073 — intervention group
Group type: COMPARATOR
Intervention: Control group (35 patients), evaluated once after 6 months.
Number of subjects: 75
Study 10359885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10359885 — intervention group
Group type: EXPERIMENTAL
Intervention: S-salbutamol 1.25 mg
Number of subjects: 11
Study 10359885 — intervention group
Group type: EXPERIMENTAL
Intervention: R-salbutamol 1.25 mg
Number of subjects: 11
Study 10359885 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic salbutamol 2.5 mg
Number of subjects: 11
Study 7794578 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem OD ER 240 mg
Number of subjects: 30
Study 7794578 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem OD ER 540 mg
Number of subjects: 30
Study 7794578 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem OD ER 360 mg
Number of subjects: 30
Study 7794578 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem OD ER 240 mg and above
Number of subjects: 30
Study 7794578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1742382 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and chlorambucil (treated group)
Number of subjects: 81
Study 1742382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 81
Study 7000264 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphinpyrazone 200 mg four times daily
Number of subjects: 98
Study 7000264 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 98
Study 30113933 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of CLS-TA 4.0 mg
Number of subjects: 22
Study 30113933 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of CLS-TA 0.8 mg
Number of subjects: 22
Study 30113933 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 27862339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling compound (CC) lotion applied twice daily for 4 weeks
Number of subjects: 70
Study 27862339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling compound (CC) lotion
Number of subjects: 70
Study 27862339 — intervention group
Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 70